Sign In
Buy OCGN
$1.21
-0.0100 (-0.82%)
At Close: Jun 12, 2026
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
09:01am, Friday, 20'th Mar 2026
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
09:01am, Friday, 20'th Mar 2026
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
09:01am, Friday, 20'th Mar 2026
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Ocugen, Inc. (NASDAQ:OCGN) Receives $9.00 Consensus PT from Analysts
01:17am, Friday, 20'th Mar 2026
Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five analysts that are currently covering the stock, Marketbeat reports. One analyst
Why Is Ocugen Stock Soaring Today?
04:21pm, Wednesday, 11'th Mar 2026
Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target.
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline
10:23am, Wednesday, 11'th Mar 2026
Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in blind
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript
01:32pm, Wednesday, 04'th Mar 2026
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates
10:26am, Wednesday, 04'th Mar 2026
Ocugen (OCGN) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.05 per share a year ago.
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
08:15am, Wednesday, 04'th Mar 2026
Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expec
MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that e
MALVERN, Pa. , Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that i
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
07:02am, Monday, 09'th Feb 2026
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the app
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
08:00am, Friday, 23'rd Jan 2026
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously a
Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering
04:37pm, Wednesday, 21'st Jan 2026
Ocugen Inc (NASDAQ: OCGN) shares sank sharply on Wednesday after the biotech company announced a $22.5 million underwritten offering of common stock.
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
08:32am, Wednesday, 21'st Jan 2026
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten
